18F-Fluorodeoxyglucose-positron emission tomography: A new explorative perspective

[1]  Tetsuya Mori,et al.  Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease , 2002, Journal of the Neurological Sciences.

[2]  V. Lowe,et al.  Biodistribution and dosimetry of [18F]fluorodeoxyglucose labelled leukocytes in normal human subjects , 2002, Nuclear medicine communications.

[3]  S. Tanada,et al.  Age-related decline of serotonin transporters in living human brain of healthy males. , 2002, Life sciences.

[4]  S. Vandenberghe,et al.  18 F-Fluorodeoxyglucose triple-headed coincidence detection imaging in oncology: preliminary results and comparison with dedicated PET. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[5]  Gunnar Brix,et al.  A survey of PET activity in Germany during 1999 , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  J. Pickard,et al.  Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography , 2002, Circulation.

[7]  K.H. Lee,et al.  Use of insulin to improve [18F]fluorodeoxyglucose labelling and retention for in vivo positron emission tomography imaging of monocyte trafficking , 2002, Nuclear medicine communications.

[8]  Hideo Tsukada,et al.  Age-related changes in cerebral blood flow and glucose metabolism in conscious rhesus monkeys , 2002, Brain Research.

[9]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[10]  S. Tanada,et al.  Oncological diagnosis using positron coincidence gamma camera with fluorodeoxyglucose in comparison with dedicated PET. , 2002, The British journal of radiology.

[11]  P. Rigo,et al.  Positron emission tomography (PET) evaluation of abdominal aortic aneurysm (AAA). , 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[12]  H J Testa,et al.  Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia , 2002, Acta neurologica Scandinavica.

[13]  L. Mortelmans,et al.  Positron emission tomography can reveal abdominal periaortitis. , 2002, Clinical nuclear medicine.

[14]  Takashi Asada,et al.  Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  G. Millonig,et al.  Atherosclerosis as an autoimmune disease: an update. , 2001, Trends in immunology.

[16]  A. Alavi,et al.  Finding infection—help from PET , 2001, The Lancet.

[17]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[18]  C. DeCarli,et al.  The role of neuroimaging in dementia. , 2001, Clinics in geriatric medicine.

[19]  S. Larson,et al.  Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. , 2001, Archives of internal medicine.

[20]  M. Tashiro,et al.  Trends in use of positron emission tomography , 2001, The Lancet.

[21]  T. Jones,et al.  In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. , 2001, Drug discovery today.

[22]  R. Moncayo,et al.  Detection of myocardial involvement in systemic lupus erythematosus: mismatch between normal perfusion scans with 201Thallium and pathological 18FDG uptake. , 2001, International angiology : a journal of the International Union of Angiology.

[23]  A. Maes,et al.  Clinical Value of [18F]fluoro-Deoxyglucose Positron Emission Tomography for Patients with Fever of Unknown Origin , 2001 .

[24]  P. Marsden,et al.  Being equipped for clinical PET , 2000, The Lancet.

[25]  C J Thompson,et al.  Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  C. Van de Wiele,et al.  Imaging of giant cell arteritis: evidence of splenic involvement using FDG positron emission tomography. , 2000, Clinical nuclear medicine.

[27]  E. Nitzsche,et al.  Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric systemic lupus erythematosus , 2000, Lupus.

[28]  S. Nishiyama,et al.  Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys , 2000, Brain Research.

[29]  A. Alavi,et al.  Nuclear imaging methods for non-invasive drug monitoring. , 2000, Advanced drug delivery reviews.

[30]  A. Maes,et al.  Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. , 2000, The American journal of medicine.

[31]  M. Schirmer,et al.  Is there a place for large vessel disease in the diagnostic criteria of Behçet's disease? , 1999, The Journal of rheumatology.

[32]  R. Moncayo,et al.  One year's clinical experience of 18F-FDG PET with a modified SPET camera using molecular coincidence detection. , 1999, Nuclear medicine communications.

[33]  R. Moncayo,et al.  Detection of Vasculitis by FDG-PET Using MCD. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[34]  C. Zouboulis.  Epidemiology of Adamantiades-Behçet's disease. , 1999, Annales de medecine interne.

[35]  J. Nuyts,et al.  New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. , 1999, Rheumatology.

[36]  Peter Bartenstein,et al.  Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system , 1999, European Journal of Nuclear Medicine.

[37]  J. Evans,et al.  Corticosteroid requirements in polymyalgia rheumatica. , 1999, Archives of internal medicine.

[38]  M. Tuszynski,et al.  Cerebral Glucose Metabolism and Memory in Aged Rhesus Macaques , 1997, Neurobiology of Aging.

[39]  W. Wilke,et al.  Large vessel vasculitis (giant cell arteritis, Takayasu arteritis). , 1997, Bailliere's clinical rheumatology.

[40]  H. Deicher,et al.  Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus , 1997, Journal of Neurology.

[41]  J. Marienhagen,et al.  High resolution single photon emission computed tomography of the brain in Wegener's granulomatosis. , 1996, The Journal of rheumatology.

[42]  G. Hunder,et al.  Increased Incidence of Aortic Aneurysm and Dissection in Giant Cell (Temporal) Arteritis: A Population-Based Study , 1995, Annals of Internal Medicine.

[43]  H. Taegtmeyer,et al.  Time course of skeletal muscle glucose uptake during euglycemic hyperinsulinemia in the anesthetized rabbit: a fluorine-18-2-deoxy-2-fluoro-D-glucose study. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  T. Terada.  [Magnetic resonance imaging in neuro-Behçet's disease--comparison with clinical, X-ray CT, and PET findings]. , 1991, Ryumachi. [Rheumatism].

[45]  Stanson Aw.  Roentgenographic findings in major vasculitic syndromes. , 1990 .

[46]  O. Schober,et al.  Positron emission tomography in neuropsychiatric lupus erythematosus , 1990, Neurology.

[47]  G. Meyer,et al.  [Imaging diagnosis of central nervous system involvement in panarteritis nodosa]. , 1989, Zeitschrift für Rheumatologie (Print).

[48]  F. Shishido,et al.  Sequential PET studies in neuro-behcet's syndrome , 1989, Journal of Neurology.

[49]  J. Tyler,et al.  Takayasu's arteritis of the aortic arch: endovascular treatment and correlation with positron emission tomography. , 1987, AJNR. American journal of neuroradiology.

[50]  G. Hunder,et al.  Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. , 1981, Arthritis and rheumatism.

[51]  G. Hunder,et al.  Polymyalgia rheumatica and giant-cell arteritis. , 1978, The New England journal of medicine.

[52]  A. Dam.  Diagnosis and pathogenesis of CNS lupus , 2004, Rheumatology International.

[53]  H. Hundeshagen,et al.  PET and MR imaging in a neuro-behçet syndrome , 2004, European Journal of Nuclear Medicine.

[54]  M. Mizuguchi,et al.  Evaluation of the significance of “redistribution” in I-123 IMP SPECT in cerebrovascular disorders—a comparative study with PET , 2004, European Journal of Nuclear Medicine.

[55]  M P Sandler,et al.  FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  P. Chieng,et al.  Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. , 1999, Arthritis and rheumatism.

[57]  P. Goodman,et al.  FDG-PET finding in early-phase Takayasu arteritis. , 1999, Journal of computer assisted tomography.

[58]  T. Ido,et al.  Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.